PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28230029
OWN - NLM
STAT- MEDLINE
DA  - 20170223
DCOM- 20170316
LR  - 20170316
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 12
IP  - Supplement
DP  - 2016 Dec
TI  - Clinical efficacy and safety of gemcitabine plus nedaplatin in the treatment of
      advanced nasopharyngeal carcinoma.
PG  - C252-C255
LID - 10.4103/0973-1482.200750 [doi]
AB  - OBJECTIVE: The purpose was to explore the clinical effects and safety of
      gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal
      carcinoma. MATERIALS AND METHODS: From March 2014 to August 2015, we recruited 63
      advanced nasopharyngeal carcinoma patients in our hospital. Moreover, the 62
      cases were randomly divided into control group (n = 31) and treatment group (n = 
      32). Patients in the control groups were treated with 5-fluorouracil 500 mg/m 2 +
      500 ml 0.9% sodium chloride injection intervenous drop infusion in day 1-5 plus
      cisplatin 20 mg/m 2 + 500 ml 0.9% sodium chloride injection intervenous drop
      infusion in day 1-5 with 21 days per cycle for 3 cycles; Moreover, patients in
      the treatment group were given gemcitabine 1000 mg/m 2 + 500 ml 0.9% sodium
      chloride injection intervenous drop infusion in day 1 and 8 plus nedaplatin 20
      mg/m 2 + 500 ml 0.9% sodium chloride injection intervenous drop infusion in day 1
      with 21 days per cycle for 3 cycles. The objective response rate (ORR) and
      chemotherapy-associated toxicities were compared between the two groups. RESULTS:
      After 3 cycle chemotherapy, the ORR was 41.9% and 78.1% in the control and
      treatment group, respectively, with statistical difference (P < 0.05); The main
      chemotherapy-related toxicity were hematological toxicity and gastrointestinal
      reaction with no statistical difference between the two groups (P > 0.05).
      CONCLUSION: The ORR was relative high for gemcitabine plus nedaplatin in the
      treatment of advanced nasopharyngeal carcinoma with main toxicity of
      hematological toxicity and gastrointestinal reaction.
FAU - Hu, Yan
AU  - Hu Y
AD  - Department of Otolaryngology, Lishui People's Hospital, Lishui, Zhejiang, China.
FAU - Fu, Jiang Tao
AU  - Fu JT
AD  - Department of Otolaryngology, Lishui People's Hospital, Lishui, Zhejiang, China.
FAU - Shi, Dongmei
AU  - Shi D
AD  - Department of Otolaryngology, People's Hospital of Xinjiang Urumqi Autonomous
      Region, Urumqi, Xinjiang, China.
FAU - Feng, Biao
AU  - Feng B
AD  - Department of Otolaryngology, Armed Police Corps Hospital, Xian, Shanxi, China.
FAU - Shi, Zhichao
AU  - Shi Z
AD  - Department of Clinical Pharmacy, Lishui People's Hospital, Lishui, Zhejiang,
      China.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Organoplatinum Compounds)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 8UQ3W6JXAN (nedaplatin)
RN  - B76N6SBZ8R (gemcitabine)
RN  - Nasopharyngeal carcinoma
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Case-Control Studies
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nasopharyngeal Neoplasms/*drug therapy/*pathology
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Organoplatinum Compounds/administration & dosage
MH  - Treatment Outcome
EDAT- 2017/02/24 06:00
MHDA- 2017/03/17 06:00
CRDT- 2017/02/24 06:00
AID - JCanResTher_2016_12_8_252_200750 [pii]
AID - 10.4103/0973-1482.200750 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2016 Dec;12(Supplement):C252-C255. doi:
      10.4103/0973-1482.200750.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>